142 results on '"Andreasson AN"'
Search Results
2. Post‐translational modifications linked to preclinical Alzheimer's disease–related pathological and cognitive changes
3. Using plasma ptau181 in Lewy Body Disease spectrum for the identification of Alzheimer’s disease co‐pathology
4. Analytical and clinical validation of a progranulin ELISA in the FTD disease spectrum
5. The cerebrospinal fluid A‐T+ Alzheimer disease biomarker profile: prevalence and clinical relevance
6. Strategy for absolute quantification of phospho‐Tau epitopes in cerebrospinal fluid by mass spectrometry
7. Blood DNA methylomic signatures associated with CSF biomarkers of Alzheimer’s disease in the EMIF‐AD Multimodal Biomarker Discovery study
8. Associations of APOE4 and Alzheimer’s disease biomarkers with cortical reinstatement and episodic memory in clinically unimpaired older adults
9. Diagnostic and Prognostic Performance of the Modified Lumipulse pTau 181 Assay in Plasma for Alzheimer’s Disease
10. Multi‐modal biomarkers improve prediction of memory function in cognitively unimpaired older adults
11. Myeloid cell bioenergetics regulate cognitive function in aging
12. Derivation of cut‐offs for plasma neurofilament light in clinical routine using healthy subjects aged between 5‐90
13. Hippocampal CA1 volume is associated with higher p‐tau and diminished memory performance in normal older adults
14. CSF Biomarkers of Amyloid and Tau Pathologies in Participants Enrolled in the Stanford Alzheimer’s Disease Research Center
15. Derivation of cut‐offs for plasma neurofilament light in clinical routine using healthy subjects aged between 5‐90
16. CSF Biomarkers of Amyloid and Tau Pathologies in Participants Enrolled in the Stanford Alzheimer’s Disease Research Center
17. Multi‐modal biomarkers improve prediction of memory function in cognitively unimpaired older adults
18. Hippocampal CA1 volume is associated with higher p‐tau and diminished memory performance in normal older adults
19. Diagnostic and Prognostic Performance of the Modified Lumipulse pTau 181 Assay in Plasma for Alzheimer’s Disease
20. Myeloid cell bioenergetics regulate cognitive function in aging
21. An examination of a novel multipanel of CSF biomarkers in the Alzheimer's disease clinical and pathological continuum
22. First amyloid β1‐42 certified reference material for re‐calibrating commercial immunoassays
23. Amyloid status is associated with deficits in connected speech language
24. Amyloid status is associated with deficits in connected speech language
25. Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum
26. DNA methylation differences associated with peripheral biomarkers in the EMIF‐AD cohort
27. Neurofilament light and cognitive performance: Associations with amyloid and vascular pathologies in individuals with mild cognitive impairment
28. Longitudinal changes in established and exploratory cerebrospinal fluid biomarkers by PTAU/AΒ 42 status in cognitively unimpaired adults
29. Replication study of plasma proteins relating to Alzheimer's pathology
30. P4-531: CEREBROSPINAL FLUID APOLIPOPROTEIN E ISOFORM CONCENTRATIONS IN RELATION TO β-AMYLOID POSITIVITY
31. An examination of a novel multipanel of CSF biomarkers in the Alzheimer's disease clinical and pathological continuum
32. DNA methylation differences associated with peripheral biomarkers in the EMIF‐AD cohort
33. Neurofilament light and cognitive performance: Associations with amyloid and vascular pathologies in individuals with mild cognitive impairment
34. Longitudinal changes in established and exploratory cerebrospinal fluid biomarkers by PTAU/AΒ 42 status in cognitively unimpaired adults
35. First amyloid β1‐42 certified reference material for re‐calibrating commercial immunoassays
36. P4‐705: TOWARD RE‐CALIBRATION OF COMMERCIAL IMMUNOASSAYS USING CERTIFIED REFERENCE MATERIALS FOR Aβ 42 IN HUMAN CEREBROSPINAL FLUID
37. O5‐05‐03: ASSOCIATIONS BETWEEN CEREBROSPINAL FLUID NEURODEGENERATIVE MARKERS, NEUROFILAMENT‐LIGHT AND TOTAL TAU AND CEREBROVASCULAR IMAGING MARKERS
38. C-terminal neurogranin is increased in cerebrospinal fluid but unchanged in plasma in Alzheimer's disease
39. O4‐02‐05: DE NOVO NAD+ SYNTHESIS RESCUES NEUROINFLAMMATION AND ALZHEIMER'S DISEASE PHENOTYPES: MODULATING IMMUNE CELL RESPONSES AND MITOCHONDRIAL BIOENERGETICS
40. P1‐279: BIMODAL DISTRIBUTION OF THE CSF Aβ42/Aβ40 RATIO IN CLINICAL LABORATORY PRACTICE
41. F1‐02‐01: RELATING CSF MARKERS NEUROGRANIN, NEUROFILAMENT‐LIGHT AND YKL‐40 TO Aβ, APOE ε4 AND COGNITION: RESULTS FROM THE EMIF‐AD MULTIMODAL BIOMARKER DISCOVERY STUDY
42. P2‐228: PRE‐ANALYTICAL STABILITY OF NOVEL CEREBROSPINAL FLUID BIOMARKERS FOR DEMENTIA
43. P2‐270: INCREASED CSF AMYLOID‐β 1‐38 AND 1‐40 CONCENTRATIONS IN INDIVIDUALS WITH MILD COGNITIVE IMPAIRMENT WITH TAU BUT WITHOUT AMYLOID PATHOPHYSIOLOGY
44. P4-535: PRESENTATION OF A ROUTINE-USE PRE-ANALYTICAL PROCEDURE FOR AD CSF BIOMARKERS
45. P1-266: COMPARISON OF A FULLY AUTOMATED BEAD-BASED SYSTEM WITH AN ENZYME-LINKED IMMUNOSORBENT ASSAY AND AN ELECTROCHEMILUMINESCENT ASSAY FOR MEASUREMENT OF CORE AD BIOMARKERS
46. O5‐05‐03: ASSOCIATIONS BETWEEN CEREBROSPINAL FLUID NEURODEGENERATIVE MARKERS, NEUROFILAMENT‐LIGHT AND TOTAL TAU AND CEREBROVASCULAR IMAGING MARKERS
47. P4-531: CEREBROSPINAL FLUID APOLIPOPROTEIN E ISOFORM CONCENTRATIONS IN RELATION TO β-AMYLOID POSITIVITY
48. P4‐705: TOWARD RE‐CALIBRATION OF COMMERCIAL IMMUNOASSAYS USING CERTIFIED REFERENCE MATERIALS FOR Aβ 42 IN HUMAN CEREBROSPINAL FLUID
49. P4-535: PRESENTATION OF A ROUTINE-USE PRE-ANALYTICAL PROCEDURE FOR AD CSF BIOMARKERS
50. P1-266: COMPARISON OF A FULLY AUTOMATED BEAD-BASED SYSTEM WITH AN ENZYME-LINKED IMMUNOSORBENT ASSAY AND AN ELECTROCHEMILUMINESCENT ASSAY FOR MEASUREMENT OF CORE AD BIOMARKERS
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.